DALLAS–(BUSINESS WIRE)–The world’s largest nonprofit funder of breast cancer research, Susan G.
Komen, today announced new advisory roles for eight leaders in breast
cancer who will guide the organization’s education and advocacy work,
public health efforts and help direct Komen’s $920
million research program – an investment in breast cancer research
surpassed only by the U.S. government.
On April 1, Jennifer A. Pietenpol, Ph.D., of Vanderbilt-Ingram
Cancer Center became Chief Scientific Advisor (CSA) for Komen. A leader
in molecular genetics and triple negative breast cancer, Dr. Pietenpol
has served as a Komen
Scholar since 2010. She joins George W. Sledge, Jr., M.D., of
Stanford University of Medicine in the CSA role, responsible for guiding
Advisory Board (SAB). As global leaders of research, clinical
practice and patient advocacy, members of Komen’s SAB help guide the
organization’s research programs and priorities.
“Jennifer Pietenpol is both a world-class breast cancer researcher and a
proven organizational leader through her directorship of Vanderbilt’s
NCI-designated Cancer Center. She is a superb addition to our
leadership,” said Dr. Sledge.
Lisa A. Newman, M.D., MPH, of Henry Ford Health System, is also
joining Komen’s SAB. A Komen Scholar since 2016, Dr. Newman’s primary
research has focused on ethnicity-related variation in breast cancer
risk and outcomes.
“An internationally known breast surgeon and breast cancer researcher,
Lisa Newman augments our Scientific Advisory Board’s expertise in
aggressive forms of breast cancer and brings a wealth of knowledge on
health disparities in breast cancer,” Dr. Sledge added. “Our Bold Goal
of reducing breast cancer mortality will benefit hugely from having
someone of her talents as part of our SAB.”
Eric Winer, M.D., of Dana-Farber Cancer Institute, whose term as CSA
ended in March, is moving into a two-year term as Past Chair of Komen’s
SAB, effective April 1. Dr. Winer was Komen’s first CSA, and has led the
SAB since its creation in 2007.
“We can’t thank Eric enough for his leadership and commitment to the
very best in breast cancer science which has helped millions of women
and men,” said Komen Board Chair Connie O’Neill. “We are looking forward
to many more years of benefitting from Eric’s expertise and his passion
for the mission to end breast cancer forever.”
The SAB terms of Amelie Ramirez, Dr.P.H., of The University of Texas
Health Science Center at San Antonio and Powel Brown, M.D., Ph.D., of
The University of Texas MD Anderson Cancer Center also ended in March.
Both leaders have made a positive, lasting impact on the organization at
both the national and local levels.
“Their generous service to our organization cannot be overstated. We are
fortunate to have benefited from their knowledge, and thankful for their
continued support,” O’Neill added.
Komen also welcomes six individuals, including two
new research advocates, to the Komen Scholars – an advisory group of
distinguished leaders in breast cancer research and advocacy who are
chosen for their knowledge and leadership within the scientific,
research and advocacy communities, and for their own contributions to
breast cancer research. These men and women lead and participate as
reviewers in Komen’s scientific peer review process, and serve as
experts and advocates for Komen’s nationwide network of Affiliates and
in communities around the globe.
The newest members to join the Komen Scholars, effective April 1, are:
Anne M. Meyn, M.Ed., Advocate in Science Steering
Committee member, Houston, TX (research advocacy)
Elizabeth A. Mittendorf, M.D., Ph.D. – The University of Texas
MD Anderson Cancer Center (immunotherapies)
Elizabeth A. Morris, M.D., FACR – Memorial Sloan Kettering
Cancer Center (diagnostic radiology)
Olufunmilayo I. Olopade, M.D. – The University of Chicago (health
Ben H. Park, M.D., Ph.D. – Johns Hopkins University (precision
Barbara Segarra-Vázquez, MT, D.H.Sc., Advocate in Science
Steering Committee member, San Juan, Puerto Rico (research advocacy)
“We are delighted to welcome these new leaders to the Komen Scholars.
Each one of them has made significant contributions to advancing breast
cancer, and are committed to helping our organization achieve its Bold
Goal of reducing the current number of breast cancer deaths in the U.S.
by 50 percent by 2026,” said Victoria Wolodzko, VP of Research and
Community Health Program Operations. “It is especially meaningful to
have two more patient advocates joining the Komen Scholars. They
constantly remind us about the realities of facing breast cancer, and
the urgent need for improving the ways breast cancer is detected,
diagnosed, treated, and ultimately cured, benefitting both Komen’s
research program and the entire field of breast cancer research in the
Since opening its doors 35 years ago, Komen has invested in breakthrough
breast cancer research spanning topics from biology to prevention,
treatment to metastasis. Komen also works in communities nationwide to
serve women and men facing breast cancer today, investing more than $2
billion in treatment, financial and psychosocial support programs to
About Susan G. Komen®
Susan G. Komen is the world’s largest breast cancer organization,
funding more breast cancer research than any other nonprofit outside of
the federal government while providing real-time help to those facing
the disease. Komen has set a Bold Goal to reduce the current number of
breast cancer deaths by 50 percent in the U.S. by 2026. Since its
founding in 1982, Komen has funded more than $920 million in research
and provided more than $2 billion in funding to screening, education,
treatment and psychosocial support programs serving millions of people
in more than 30 countries worldwide. Komen was founded by Nancy G.
Brinker, who promised her sister, Susan G. Komen, that she would end the
disease that claimed Suzy’s life. That promise has become Komen’s
promise to all people facing breast cancer. Visit komen.org
or call 1-877 GO KOMEN. Connect with us on social at ww5.komen.org/social.
Susan G. Komen
Joni Avery, 972-855-4382